跳至主要内容
临床试验/PACTR201912897645869
PACTR201912897645869尚未招募2 期

Safety and efficacy of photodynamic therapy (with riboflavin as sensitizer) for treatment of malaria in adult Nigerian population: a Phase II study

Future Minds Development Initiative0 个研究点目标入组 200 人开始时间: 2019年11月28日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
All

入选标准

  • Patients older than 18 years of age,
  • Not on any form of treatment or prophylaxis for malaria, and
  • Who gave an informed consent to participate in the study.

排除标准

  • Patients with complicated malaria (haemolytic anaemia, cerebral malaria, algid malaria,
  • nephropathy etc),
  • Those who are on antimalarial treatment or prophylaxis,
  • Pregnant and lactating mothers,
  • Those with concurrent or underlying illnesses,
  • Those with known drug allergy, and
  • Those who did not give informed consent will be excluded from the study.

研究者

发起方
Future Minds Development Initiative

相似试验